SM News Briefs

Rare Care podcast logo

Dr. Federico Stella on Using Nonrestrictive Diets After Stem Cell Transplantation

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Federico Stella, MD, on the controversial practice of severely restricting the diets of patients who have just undergone stem cell transplants. Read the full story here: Italian Hematologist Urges End to ‘Useless’ Restrictive Diets After Stem Cell Transplants

Bone density scan

Bone Mass Loss, Diffuse Bone Sclerosis Observed in Patients With SM

The routine measurement of bone remodeling biomarkers should be performed in all patients with systemic mastocytosis (SM), according to findings from a cross-sectional study published in The Journal of Allergy and Clinical Immunology: In Practice. In patients with SM, tissue accumulation of clonal mast cells often includes bone involvement. Although several mast cell mediators, such…

Protein illustration

CCL23 Suggested as a Potentially Relevant Biomarker in Systemic Mastocytosis

CCL23 (chemokine ligand 23) has been suggested as a biomarker for systemic mastocytosis (SM), with CCL23 plasma cells associated with disease severity, according to findings from a study published in The Journal of Allergy and Clinical Immunology. SM has been described as a heterogeneous group of disorders in which accumulation of neoplastic mast cells in…

patient questionnaire

Avapritinib Could Reduce Indolent Systemic Mastocytosis Disease Burden

Avapritinib (Ayvakit®) plus best supportive care improved symptoms and quality of life (QoL) in patients with indolent systemic mastocytosis (SM), according to results from the registrational PIONEER trial. The findings will be presented in a poster at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting being held February 24 to 27, 2023, in…

Mastocytosis skin

PIONEER Trial Suggests Avapritinib Ameliorates Indolent SM Skin Symptoms

Results from the registrational PIONEER trial suggest that avapritinib (Ayvakit®) improves skin signs and symptoms in patients with indolent systemic mastocytosis (SM). The results will be presented in a late-breaking presentation at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting being held February 24-27 in San Antonio, Texas. “Avapritinib-treated patients experienced…

man with fatigue

Nonadvanced Systemic Mastocytosis Can Have Severe and Debilitating Effects

Individuals with nonadvanced systemic mastocytosis (SM) experience a myriad of severe, debilitating symptoms that can impact their health-related quality of life (HRQoL), according to findings from 90-minute qualitative virtual interviews conducted among US adult patients with the disease. Results of the study will be presented at the 2023 American Academy of Allergy, Asthma & Immunology…


Case Presentation Details Cardiac Surgery Anaphylaxis in a Patient With SM

The case presentation of a female patient with systemic mastocytosis (SM) who suffered a life-threatening anaphylactic reaction during cardiac surgery, as well as a systematic review of the related literature, was recently published in the Journal of Clinical Medicine. The authors reported on the case of a 66-year-old woman admitted for planned aortic valve replacement.…

elderly man with doctor

Analysis Finds High Incidence of Avapritinib-Related Adverse Events in Elderly Men

A postmarketing pharmacovigilance analysis of avapritinib, a medication used in the treatment of systemic mastocytosis (SM), discovered that elderly male patients were at an increased risk of experiencing serious adverse events related to treatment. The study was published in the British Journal of Clinical Pharmacology. The study authors extracted 3120 avapritinib-related reports submitted to the US…

Next post in SM News Briefs